What are the implications of the STAR*D trial for primary care? A review and synthesis

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 10, Issue 2, 2008, Pages 91-96

  Huynh, Nhu N ^a   McIntyre, Roger S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; BUPRENORPHINE; BUSPIRONE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CITALOPRAM; ESTROGEN; INOSITOL; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MODAFINIL; NORTRIPTYLINE; OLANZAPINE; PINDOLOL; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; HEALTH PRACTITIONER; HUMAN; INSURANCE; MAJOR DEPRESSION; MEDLINE; MONOTHERAPY; PATIENT SELECTION; PRIMARY MEDICAL CARE; RANDOMIZATION; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VALIDITY;

EID: 45749151826     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v10n0201     Document Type: Article

References (26)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242
3. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
4. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007;164:739-752
5. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-1172
6. 3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163:1519-1530
7. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-1541
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
9. University of Pittsburgh. Sequenced Treatment Alternatives to Relieve Depression. Available at: http://www.edc.pitt.edu/stard/public/. Accessed Dec 27, 2007
10. McIntyre RS, Muller A, Mancini DA, et al. What to do if an initial antidepressant fails? Can Fam Physician 2003;49:449-457
11. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(suppl 13):23-29
12. Thase ME. Pharmacologic strategies for treatment-resistant depression: an update on the state of the evidence. Psychiatr Ann 2005;35:970-980
13. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry 2007;68(suppl 8):17-25
14. Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19-29
15. Snow VS, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. Ann Intern Med 2000;132:738-742
16. Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders, 4: medications and other biological treatments. Can J Psychiatry 2001;46(suppl 1):38-58
17. Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999 March;60(3):142-156
18. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007:8:67-104
19. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917
20. Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007;164:201-204
21. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841-1853
22. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60(suppl 22):29-34
23. Reesal RT, Lam RW. Clinical guidelines for the treatment of depressive disorders, 2: principles of management. Can J Psychiatry 2001;46(suppl 1):21-28
24. Weissman M, Pilowsky DJ, Wickramarathne PJ, et al. Remissions in maternal depression and child psychopharmacopathology, a STAR*D-child report. JAMA 2006;295:1389-1398
25. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-613
26. McIntyre RS, Konarski JZ, Mancini DA, et al. Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ 2005;173:1327-1334